Volume 8, Number 2—February 2002
Synopsis
Current Status of Antimicrobial Resistance in Taiwan
Figure

Figure. . A, Macrolides consumption (gram x 1000,000) in Taiwan and the trends of erythromycin-resistant group A Streptococcus (EM-R GAS), group B Streptococcus (EM-R GBS), and S. pneumoniae in National Taiwan University Hospital from 1991 to 2000. Macrolides include intravenous and oral forms of erythromycin and oral forms of clarithromycin, roxithromycin, and azithromycin. B,. Distribution of erythromycin-resistant M-phenotype among isolates of streptococci. Other streptococci include Groups C, F, and G, and viridans group streptococci. Number in each bar indicates the percentage of erythromycin-resistant isolates. Number above each bar indicates the percentage of M-phenotype among erythromycin-resistant isolates.
Page created: April 18, 2012
Page updated: April 18, 2012
Page reviewed: April 18, 2012
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.